A new study has validated Neoteryx’s VAMS technology for at-home blood collection in monitoring HbA1c levels of diabetic children.
Image: Neoteryx’s VAMS technology backed by new research. Photo: Courtesy of Neoteryx, LLC.
announced research recently published in the official peer-reviewed scientific journal of the European Federation of Clinical Chemistry and Laboratory Medicine, Clinical Chemistry and Laboratory Medicine.
The research found that analysis of samples extracted from the company’s VAMS™ technology showed almost perfect agreement with results obtained from venous blood samples for HbA1c levels on a Tosoh G8 analyzer.
The investigator-initiated clinical research study took place from June 2017 to January 2018 at Ghent University Hospital in Belgium. The study included 100 patients and was approved by the school’s Ethics Committee.
Ghent University Laboratory of Toxicology director and one of the authors of the study Christophe Stove said: “VAMS technology allows convenient at-home monitoring and is minimally invasive. It also offers efficiencies in the clinical setting, as providers will have blood results in hand before meeting with the patient.
“Monitoring Type 1 diabetes in children is challenging for families. We’re constantly evaluating solutions to make the monitoring process more efficient. This study substantiates that wet-absorptive microsampling using Neoteryx’s VAMS technology provides clinically-viable results while simplifying patients’ lives, streamlining provider visits and easing the challenges of managing this disease.”
The objective of this study was to evaluate whether adjustments to the sample protocol would allow combining the simplicity of VAMS-based home sampling with clinically-acceptable results. In a paper originally published in 2017 on HbA1c analysis with the dried blood microsamples using VAMS, the researchers found the results deviated from the venous blood samples. The transition to wet-absorptive microsamples made the difference with a fixed volume of approximately 10 µL of blood using the absorbent tip of Neoteryx’s VAMS device.
Neoteryx chief scientific officer Stuart Kushon said: “We are pleased with the results of Dr. Stove’s research and how the wet-absorptive tip yielded clinically-acceptable results with high patient satisfaction. This research underscores the importance of microsampling.
“The goal of Neoteryx is to allow for convenient blood collection at any time by anyone in any location. If we can do that for children managing their diabetes and make things easier for them, we are achieving that goal.”
Source: Company Press Release.